Vol. 40 | No. 1 | January-June 2012 Back

Open Access

Achromobacter Xylosoxidans Late-onset Prosthetic Mitral Valve Infective Endocarditis: A Case Report

Paul Ferdinand M. Reganit, Luna Parreno, Roman Santos
Jun 2012 DOI 10.69944/pjc.c61820e8af

Abstract

This is the case of a 35-year-old Filipino female who presented to the Philippine General Hospital with a chief complaint of fever. Two weeks prior to admission, she experienced high-grade fever (39 degrees Celsius) accompanied by chills, anorexia, and easy fatigability. A few hours prior to admission, she complained of slurred speech, right upper and right lower extremity weakness, and high-grade fever. She was diagnosed with rheumatic heart disease in the past, with mitral stenosis, and atrial fibrillation. She has undergone prosthetic mitral valve replacement. She denies intravenous drug use. 

On examination, she was awake, with stable vital signs and a body temperature of 39 degrees Celsius. Auscultation revealed an irregular heart rhythm, metallic S1, accentuated S2, and a 3/6 systolic murmur at the fourth left paqrasternal border. Motor strength was normal. 

She had leukocytosis (11.6 X 109 cells/L)þ and nromal coagulation profile. Transthoracic echocardiography revealed a dilated left atrium, a prosthetic mitral valve with good opening and closing motion, and a 0.2 x 0.4 cm oscillating mass in the ventricular aspect of the mitral valve. Blood cultures revealed Achromobacter xylosoxidans sensitive to piperacillina-tazobactam, co-trimoxazole, and ciprofloxacin. 

Piperacillin-tazobactam 4.5 g IV every 8 hrs and co-trimoxazole 800/160, 1 tab po every 8 hrs were given; however, due to resulting leukopenia, ciprofloxacin 500 mg/tab 1 ½ tab po q 12 hrs was substituted. Surveillance blood cultures were all negative. A follow-up transesophageal echocardiography revealed a prosthetic mitral valve with good opening and closing motion with no vegetations seen. 

CONCLUSION: A xylosoxidans is a rare human pathogen and causes invasive disease such as infective endocarditis in immunocompromised and debilitated patients resulting in high mortality. Prompt and effective use of antimicrobials improves survival, but removal of prostheses may be considered in the presence of unresponsive or recurrent infection. 

KEYWORDS: Achromobacter xylosoxidans, prosthetic valve, infective endocarditis

References
  1. Yabuuchi E, Oyama A. Achromobacter xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol. 1971 Sep;15(5):477-81.
  2. Shie SS, Huang CT, Leu HS. Characteristics of Achromobacter xylosoxidans bacteremia in northern Taiwan. Microbiol Immunol Infect. 2005 Aug;38 (4):277-82. 
  3. Lofgren RP, Nelson AE, Crossley KB. Prosthetic valve endocarditis due to Achromobacter xylosoxidans. Am Heart J. 1981 Apr;101(4):502. 
  4. Bonow RO, Mann DL, Zipes DP, Peter P. Braunwald’s Heart Disease 9th edition. St. Louis: Elsevier, 2012 
  5. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH; International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Arch Intern Med. 2009 Mar 9;169(5):463-73. 
  6. Aisenberg G, Rolston KV, Safdar A. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer. 2004 Nov 1;101(9):2134-40. 

 

License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.